Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Cash & Equivalents (2016 - 2025)

Orthopediatrics (KIDS) has disclosed Cash & Equivalents for 10 consecutive years, with $19.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 55.37% to $19.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.6 million, a 55.37% decrease, with the full-year FY2025 number at $19.6 million, down 55.37% from a year prior.
  • Cash & Equivalents was $19.6 million for Q4 2025 at Orthopediatrics, up from $16.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $51.0 million in Q3 2024 to a low of $6.3 million in Q3 2021.
  • A 5-year average of $24.0 million and a median of $21.4 million in 2021 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 92.83% in 2021, then skyrocketed 379.77% in 2024.
  • Orthopediatrics' Cash & Equivalents stood at $7.6 million in 2021, then increased by 17.67% to $9.0 million in 2022, then skyrocketed by 245.4% to $31.1 million in 2023, then soared by 41.1% to $43.8 million in 2024, then crashed by 55.37% to $19.6 million in 2025.
  • Per Business Quant, the three most recent readings for KIDS's Cash & Equivalents are $19.6 million (Q4 2025), $16.8 million (Q3 2025), and $44.6 million (Q2 2025).